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Abstract: Metal complexes of a heterocyclic sulfonamides possessing very strong carbonic anhydrase (CA)
inhibitory properties, i.e., 5-(p-fluorobenzenesulfonylamido)-l,3,4-thiadiazole-2-sulfonamide (p-fluoro-
benzolamide) were prepared. The new complexes contained metal ions such as Zn(II), Cu(II), Co(II), Ni(II),
Cd(II) and Mn(II). The new compounds were characterized by standard physico-chemical procedures, and
assayed as inhibitors of three CA isozymes, CA I, II and IV. Very good inhibition has been evidenced both
for the parent sulfonamides as well as for the prepared complexes, against all three investigated isozymes.
Some ofthese new complexes as well as the parent sulfonamide, strongly lowered intraocular pressure (lOP)
in normotensive rabbits when administered as a 2% solution into the eye.
Introduction
The sulfonamides represent an important class of biologically active compounds, with at least five
different classes ofpharmacological agents that have been obtained from the sulfanilamide structure as lead,
the derivative initially studied by Domagk [2] as the first modem chemotherapeutic drug. Indeed, the
antibacterial sulfonamides [3] continue to play an important role in chemotherapy, alone or in combination
with other drugs [4], the sulfonamides that inhibit the zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1)
possess many applications as diuretic, antiglaucoma or antiepileptic drugs among others [5-7], the
hypoglycemic sulfonamides are extensively used in the treatment ofsome forms of diabetes [8], whereas the
thiazides and high-ceiling diuretics might be considered as a fortunate development ofthe CA inhibitors [9],
but these compounds possess a different pharmacological profile, independent of CA inhibition 10,11 ].
Finally, some antithyroid drugs have also been developed starting from the sulfonamide structure as lead
molecule 12].
The second class of the above mentioned pharmacological agents, i.e., the sulfonamides with CA
inhibitory action, have thoroughly been investigated in the last 10 years, mainly in the search of a topically
effective antiglaucoma drug [13-19]. The possibility of administering a sulfonamide via the topical route
directly into the eye, although investigated in the 1950-s [20,21 ], has been totally unsuccessful, whereas the
systemic administration, quite useful in lowering intraocular pressure (lOP), was generally accompanied by
undesired side effects, due to CA inhibition in other tissues than the eye [21]. In 1983, Maren’s group [13]
postulated that a water-soluble sulfonamide, also possessing a relatively balanced lipid solubility, would be
an effective IOP lowering drug via the topical route, but at that moment no inhibitors possessing such
physico-chemical properties existed. They started to be developed in several laboratories soon thereafter 13-
19], and in 1995 the first such pharmacological agent, dorzolamide 1 entered in clinical use in USA and
Europe [22]. A second compound, brinzolamide 2, quite similar structurally with dorzolamide has also
recently been approved for the topical treatment ofglaucoma in USA [23].
In addition to the above-mentioned sulfonamides, we developed in our laboratory the synthesis and
characterization of CA inhibitors based on the classical ring systems containing the 1,3,4-thiadiazole-2-
sulfonamide moiety [24-26]. Thus, some derivatives structurally related to benzolamide 3, such as its p-
fluoro- congener 4, proved to act as very strong in vitro CA inhibitors, possessing at the same time a larger
water solubility as compared to the classical clinically used inhibitors, such as acetazolamide 5 for instance
[27]. Since we have recently shown that metal complexes of aromatic/heterocyclic sulfonamides possess
strong antiglaucoma action in normotensive and glaucomatous rabbits [28,29], it appeared of interest to
obtain metal complexes of a benzolamide-like compound, and the p-fluoro-derivative 4 proved to be an
interesting candidate for such a study.


















In this paper we report the synthesis of metal complexes containing the conjugate base of
sulfonamide 4 as ligand, and divalent metal ions such as Zn(II), Cu(II), Co(II), Ni(II), Cd(II) and Mn(II).
The new compounds reported here were characterized by standard physico-chemical procedures and assayed
for inhibition against three physiologically relevant CA isozymes, hCA I, hCA II and bCA IV (h human,
b bovine isozyme). Good inhibition has been observed with all the new complexes, and especially with
the Zn(II) and Cu(II) derivatives. In vivo data in normotensive rabbits proved that both the parent
sulfonamide as well as its Zn(II) and Cu(II) complexes behave as strong antiglaucoma agents, with a potency
comparable to that of dorzolamide, the clinically used drug.
Materials and Methods
Melting points were recorded with a heating plate microscope and are not corrected. IR spectra were
recorded in KBr pellets with a Carl Zeiss IR-80 instrument. 1H-NMR spectra were recorded in DMSO-d6 as
solvent, with a Bruker CPX200 instrument. Chemical shifts are reported as values, relative to Me4Si as
internal standard. Conductimetric measurements were done at room temperature (1 mM concentration of
complex) in DMSO solution with a Fisher conductimeter. Elemental analyses were done by combustion for
C, H, N with an automated Carlo Erba analyzer, and gravimetrically for the metal ions, and were 0.4% of
the theoretical values. Thermogravimetric measurements were done in air, at a heating rate of 10C/min.,
with a Perkin Elmer 3600 thermobalance.
Sulfonamides used as standards in the enzymatic assay (except for 1), acetazolamide, 4-
fluorobenzenesulfonyl chloride used for the preparation ofcompound 4, solvents as well as inorganic reagents
were from Sigma, E. Merck and Aldrich. 5-Amino-l,3,4-thiadiazole-2-sulfonamide was prepared from
acetazolamide by literature procedures [27], by desacetylation with concentrated hydrochloric acid, followed
by neutralization with sodium bicarbonate of the corresponding hydrochloride. Dorzolamide hydrochloride 1
was from Merck, Sharp and Dohme or was prepared as described by Ponticello et al 15].
Human CA I and CA II cDNAs were expressed in Escherichia coli strain BL21 (DE3) from the
plasmids pACA/hCA I and pACA/hCA II described by Forsman et al. [30] (the two plasmids were a gift
from Prof. Sven Lindskog, Umea University, Sweden). Cell growth conditions were those described by
Lindskog’s group [31 ], and enzymes were purified by affinity chromatography according to the method of
Khalifah et al [32]. Enzyme concentrations were determined spectrophotometrically at 280 nm, utilizing a
molar absorptivity of 49 mM’l.cm"l for hCA I and 54 mM’l.cm-1 for hCA II, respectively, based on Mr
28.85 kDa for hCA I, and 29.3 kDa for hCA II, respectively [33,34]. bCA IV was isolated from bovine lung
microsomes as described by Maren et al, and its concentration has been determined by titration with
ethoxzolamide [35].
Synthesis of5-(p-fluorobenzenesulfonamido)-1, 3,4-thiadiazole-2-sulfonamide 4
An amount of 1.80 g (10 mmol) of 5-amino-l,3,4-thiadiazole-2-sulfonamide was suspended in 20 mL of
acetone and 50 mL of water. The mixture was magnetically stirred at 4 C for 10 minutes, then 10.5 mmol
of 4-fluorobenzenesulfonyl chloride, dissolved in 10 mL acetone, and a solution obtained from 0.40 g of
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NaOH in 10 mL of water were added dropwise for 30 min, and stirring was continued for other 2 hours at 4
C. After evaporation of the acetone and neutralization of the reaction mixture with 5 % HC1 solution, the
precipitated crystals were filtered and recrystallized from ethanol. Yield of 68%, as white crystals, m.p. 193-
195 lit [27] m.p. 192-194C (from ethanol-water 1:1, v/v); IR (KBr), cm"1:684, 715, 883, 1132, 1170,
1284, 1357, 1380, 1425, 1572, 1604, 3065; 1H-NMR (DMSO-d6), (5, ppm): AA’BB’,4H,ArH:, 5(A) 7.21,
5(B) 7.40 ppm, J 7.8 Hz); 8.03 (br s,2H, SO2NH2); 8.22 (s, lH, SO2NH); 13C-NMR (DMSO-d6), (5,
ppm: 118.1; 118.7; 130.0; 130.9; 160.1 (C-2 from thiadiazole); 173.1 (C-5 from thiadiazole). Anal., found:
C, 28.63; H, 2.00; N, 16.39 %; CsHTFN404S3 requires: C, 28.40; H, 2.09; N, 16.56 %.
Generalprocedurefor the preparation ofcomplexes 6-11
An amount of 6 mmol of sodium salt of sulfonamide 4 was prepared by reacting the corresponding
sulfonamide with the required amount of an alcoholic 1N NaOH solution, in ethanol as solvent. To this
solution was added the aqueous metal salt solution (Zn(II), Cu(II), Co(II), Cd(II), Mn(II) chlorides, and
Ni(II) sulfate), working in molar ratios RSO2NH" Mn/ of 2:1. The aqueous-alcoholic reaction mixture was
heated on a steam bath for one hour, adjusting the pH at 7 if necessary, and after being cooled at 0 C the
precipitated complexes were filtered and thoroughly washed with alcohol-water 1:1 (v/v) and air dried. Yields
were in the range of 85-90 %. The obtained powders of compounds 6-11 melted with decomposition at
temperatures higher than 350 C, and were poorly soluble in water and alcohol, but had good solubilities in
DMSO, DMF as well as mixtures of DMSO-water, DMF-water.
Pharmacology
Carbonic anhydrase inhibition
Initial rates of 4-nitrophenyl acetate hydrolysis catalysed by different CA isozymes were monitored
spectrophotometrically, at 400 nm, with a Cary 3 instrument interfaced with an IBM compatible PC [36].
Solutions of substrate were prepared in anhydrous acetonitrile; the substrate concentrations varied between
2.10-2 and 1.10-6 M, working at 25C. A molar absorption coefficient e of 18,400 M’.cm" was used for the
4-nitrophenolate formed by hydrolysis, in the conditions of the experiments (pH 7.40), as reported in the
literature [36]. Non-enzymatic hydrolysis rates were always subtracted from the observed rates. Duplicate
experiments were done for each inhibitor concentration, and the values reported throughout the paper are the
mean of such results. Stock solutions of inhibitor (1 mM) were prepared in distilled-deionized water with 10-
20% (v/v) DMSO (which is not inhibitory at these concentrations [5]) and dilutions up to 0.01 nM were
done thereafter with distilled-deionized water. Inhibitor and enzyme solutions were preincubated together for
10 min at room temperature prior to assay, in order to allow for the formation of the E-I complex. The
inhibition constant KI was determined as described by Pocker and Stone [36]. Enzyme concentrations were
3.3 nM for hCA II, 10 nM for hCA and 34 nM for bCA IV (this isozyme has a decreased esterase activity
[37] and higher concentrations had to be used for the measurements).
Measurement oftonometric 10P
Adult male New Zealand albino rabbits weighing 2-3 kg were used in the experiments (three animals were
used for each inhibitor studied). The experimental procedures conform to the Association for Research in
Vision and Ophthalmology Resolution on the use of animals. The rabbits were kept in individual cages with
food and water provided ad libitum. The animals were maintained on a 12 h: 12 h light/dark cycle in a
temperature controlled room, at 22-26 C. Solutions of inhibitors (2 %, by weight) were obtained in DMSO-
water (2:3, v/v) due to the low water solubility of some of these derivatives. Control experiments with
DMSO (at the same concentration as that used for obtaining the inhibitors solutions showed that it does not
possess IOP lowering or increasing effects.
IOP was measured using a Digilab 30R pneumatonometer (BioRad, Cambridge, MA, USA) as
described by Maren’s group [38-40]. The pressure readings were matched with two-point standard pressure
measurements at least twice each day using a Digilab Calibration verifier. All IOP measurements were done
by the same investigator with the same tonometer. One drop of 0.2 % oxybuprocaine hydrochloride
(novesine, Sandoz) diluted 1"1 with saline was instilled in each eye immediately before each set of pressure
measurements. IOP was measured three times at each time interval, and the means reported. IOP was
measured first immediately before drug administration, then at 30 min after the instillation of the
pharmacological agent, and then each 30 minutes for a period of several hours. For all IOP experiments drug
was administered to only one eye, leaving the contralateral eye as an untreated control. The ocular
hypotensive activity is expressed as the average difference in IOP between the treated and control eye, in this
way minimizing the diurnal, seasonal and interindividual variations commonly observed in the rabbit [38-
40]. All data are expressed as mean + SE, using a one-tailed test.
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Results and Discussion
Reaction of 5-amino-l,3,4-thiadiazole-2-sulfonamide with 4-fluorobenzenesulfonyl chloride in
Schotten-Baumann conditions afforded 5-(p-fluorobenzenesulfonylamido)-1,3,4-thiadiazole-2-sulfonamide 4,
by the procedure already reported previously by this group [27].
Metal complexes 6-11 containing the conjugate base of sulfonamide 4 (LH) and divalent metal ions,
and their elemental analysis data are shown in Table I.
Table I: Prepared complexes 6-11, containing the conjugate base of sulfonamide 4 (LH) as ligand and their
elemental analysis data. L stands for the primary sulfonamide deprotonated species of 4.
No. Complex Yield Analysis (calculated/found)
(%) %Ma %Cb %Hb %Nb
6 [MnL2(OH2)2] 75 7.1/7.5 25.0/25.1 2.0/1.7 14.6/14.3
7 [NiL2(OH2)2] 65 7.6/7.2 24.9/24.9 2.0/2.3 14.5/14.4
$ [CoL2(OH2)2 80 7.6/8.0 24.9/25.2 2.0/2.1 14.5/14.1
9 [CuL2(OH2)2] 84 8.2/8.1 24.8/24.9 2.0/2.1 14.4/14.3
10 [ZnL2] 87 8.8/8.7 25.9/25.6 1.6/1.3 15.1/15.0
11 [CdL2] 90 14.2/14.2 24.4/24.5 1.5/1.7 14.2/14.3
aBy gravimetry; bBy combustion.
The new complexes have also been characterized by spectroscopic, conductimetric and
thermogravimetric measurements (Table II). By comparing the IR spectra of the complexes and the free
ligand, the following differences were evidenced: (i) the shift of the two sulfonamido vibrations (both the
symmetric as well as the asymmetric one), towards lower wavenumbers in the spectra of the complexes, as
compared to the spectra ofthe corresponding ligand (Table II), as already documented previously for similar
complexes [25-29]. One should note that only one pair of such vibrations underwent the above-mentioned
shift, presumably those of the primary sulfonamido moiety, whereas the secondary sulfonamide (p-F-
C6H4SO2NH) moiety appeared at the same wavenumbers both in 4 as well as its metal complexes, i.e., at
1132 and 1357 cm-1, respectively (data not shown). This is a direct indication that the deprotonated primary
sulfonamido moiety of the ligand interacts with the metal ions in the newly prepared coordination
comlpounds; (ii) the C=N stretching vibration in the spectra of the prepared complexes is shifted with 14-21
cm"towards lower wavenumbers, as compared to the same vibration in the spectrum of sulfonamide 4
indicating that one of the endocyclic nitrogens ofthe thiadiazolic ring (presumably N-3) acts as donor atom,
as already documented by X-ray crystallographic and spectroscopic determinations on complexes of other
sulfonamides (such as benzolamide 3) with divalent metal ions [41] (Table II); (iii) changes in the region
3100-3160 cm", as the bands present in the spectra of sulfonamide 4 are present in the spectra of complexes
6-11 too, but they are not well resolved, and have a smaller intensity. This is probably due to deprotonation
ofthe SO2NH2 moiety and participation in the binding of cations (data not shown).
Table II: Spectroscopic, thermogravimetric and conductimetric data for compounds 4-11.






AM (f2-1 x cm2x mol-1)
4 1170; 1380 1604 3
6 1150; 1350 1583 25500; 24200; 19700 4.7/5.0e 5
7 1150; 1360 1580 24100; 17500; 11050 4.6/4.5e 6
8 1150; 1355 1584 26300; 19850; 17100 4.6/4.8e 8
9 1155; 1350 1590 25000; 16900; 14350 4.6/4.5e 5
10 1145; 1350 1586 f 4
11 1140; 1300 1590 f 7
a In KBr; bin MgO as standard, by the diffuse reflectance technique; cWeight loss between 70-250 C; d
mM solution, in DMF, at 25C; eCorresponding to two coordinated water molecules lost at 150-170C, f
No weight loss seen under 250 C.
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Diffuse reflectance electronic spectroscopic data (for paramagnetic transition metal ions) helped us to
establish the geometry of the cations in the prepared complexes 6-9 (Table II). Thus, octahedral structures
were detected for the majority of the prepared complexes (such as the Mn(II); Ni(II); Co(II); and Cu(II)
derivatives), whereas tetrahedral geometries were proposed for the Zn(II) and Cd(II) complexes 10 and 11,
based on the stoichiometry and analogy with other structurally related compounds [41-45], which have been
characterized by means ofX-ray crystallography [41 ]. TG data confirmed the above-mentioned statements, as
two coordinated water molecules were detected in the octahedral complexes 6-9, whereas conductimetric
measurements proved the non-electrolyte nature of all these complexes (Table II).
Thus, similarly to benzolamide 3 [41], the donor system of p-flluorobenzolamide 4 probably
consists of the sulfonamido nitrogen and endocyclic N-3 atoms when interacting in deprotonated state with
the metal ions considered in the present work. Proposed structures for the obtained complexes are shown
below.
Table III. CA inhibition data with the standard inhibitors 1-5, and the metal complexes 6-11 against
isozymes CA I, II and IV.
No Inhibitor KI (nM)
hCA Ia hCA IIa bCA IVb
1 Dorzolamide 50000 9 45
2 Brinzolamide 3 45
3 Benzolamide 15 9 12
4 p-Fluorobenzolamide 4 4 7
5 Acetazolamide 900 12 220
6 3 2 5
7 4 3 2
$ 3 2 2
9 2 2 4
10 3 1.5 3
11 2 2 3
a Human (cloned) isozymes; b From bovine muscle; c From bovine lung microsomes.
The complexes 6-11 together with .the standard CA inhibitors 1-5 were assayed for inhibition
against four isozymes, hCA I, hCA II, and bCA IV (Table III). As seen from the above data, p-
fluorobenzolamide 4, the ligand used for preparing metal complexes, is more inhibitory than acetazolamide,
benzolamide or dorzolamide, having similar potency with brinzolamide against hCA II, but being a much
better inhibitor against bCA IV, as compared to the latter sulfonamide. The metal complexes 6-11 are much
more inhibitory than the sulfonamide from which they derive 4, and than all other simple sulfonamides
assayed. They behave similarly to the metal complexes of acetazolamide, methazolamide or dorzolamide
previously reported by this group, which were all more inhibitory than the parent sulfonamide from which
were prepared [26,28,29].
Particularly strong inhibition was observed for the Cd(II); Zn(II) and Cu(II) complexes, especially against
CA II and CA IV, the isozymes critical for aqueous humor formation, but all these metal complexes act as
particularly powerful CA inhibitors.
In vivo lOP lowering experiments were done in rabbits with .the new compounds prepared in the
present work, as well as the sulfonamides I and 4 for comparison. Some of the lOP lowering data at half an
hour and one hour after the instillation of one drop of 2 % solution of inhibitor within the rabbit eye are
shown in Table IV, with dorzolamide I (at the same concentration) as standard.
As seen from the above data, the sulfonamide 4 is a much more effective lOP lowering agent, as
compared to the clinically used compound dorzolamide, at all periods of measurement. From the data of
table IV, it is obvious that the metal complexes of sulfonamide 4, of types 6-11, investigated by us behave
as much more effective lOP lowering agents than dorzolamide or the parent ligand 4. The most effective
cations for the lOP lowering effect were Zn(II), Cu(II) and Cd(II). A remarkable f’mding consists in the fact
that the metal complexes seem to possess a much longer duration of action ofthe IOP lowering effect, as seen
from the measurements done at one and a halfhour, which show a reduced pressure (ofmore than 7 mm Hg),
whereas dorzolamide already lost much of its effect. Probably the pharmacokinetic properties of such metal
complexes constitute a valuable feature for developing novel types of more effective topical antiglaucoma
drugs from this class ofcompounds.














1 1: M = Cd
Table IV: lOP lowering following topical application ofCA inhibitors, half an hour, one hour and one and a
half hours after instillation into the eye of a drop (50 (L) of 2 % solution of inhibitor in DMSO-water (2:3,
v/v).
Inhibitor AIOP _+ SE a
(mm Hg)









2.2 ( 0.10 4.1 ( 0.15 2.7( 0.08
5.0 (0.10 7.3 ( 0.09 6.4( 0.11
5.9 (0.10 7.8 ( 0.10 7.0( 0.06
6.0(0.09 8.0 ( 0.12 7.3( 0.08
8.0 (0.14 8.5 ( 0.21 7.4( 0.07
8.0 (0.10 8.4 ( 0.09 7.7( 0.09
9.3(0.09 12.5 ( 0.12 8.6( 0.12
8.0 (0.14 8.1 ( 0.21 7.7( 0.08
a AIOP =IOP control eye IOP treated eye (N 3).
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